demonstrated that anti-PD-L1 (Avelumab) targeting PD-L1+ HIVGag-specific-CD8+ T-cells combined with rhIL-15 enhanced CD8+ T-cell activity during HIV infection (84). This evidence concerns the gene CD274 and HIV infectious disease.